Iambic
IAM
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-10-15
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-0.90~-0.80
-
-
711.01M~805.81M
-
2026-10-08
Public Filing
View Prospectus
Pending
Offering
Price Range: 15.00~17.00
Shares to be Issued: 9375.00K
2026-10-14
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 47.40M
2026-10-15
Listed
No Data
About IAM
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company. Its molecular superintelligence platform integrates proprietary AI technologies with automated, scalable chemistry and biology experimentation. Its pipeline of drug candidates is developed using a molecular superintelligence platform. IAM1363, is a HER2 inhibitor that is in a Phase I/Ib clinical trial in subjects with HER2-altered solid tumors. The Company's additional programs, IAM217 (KIF18A inhibitor) and IAM-C1 (dual CDK2/4 inhibitor), are in preclinical development. IAM1363 is an oral, selective, pan-mutant, and brain-penetrant small molecule inhibitor that selectively targets HER2 and HER2 mutants, while sparing EGFR. Amplification and mutations of HER2 drive a wide range of human cancers. IAM-C1 is a small-molecule inhibitor with a differentiated selectivity profile, designed to specifically target CDK2 and CDK4, two cell-cycle kinases that are frequently dysregulated in various cancers.

Webull offers Iambic stock information, including NASDAQ: IAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IAM stock methods without spending real money on the virtual paper trading platform.